Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Paola Squarcina
Observed names:
P Squarcina,
P. Squarcina
Institution:
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institutions:
University of Siena,
The Wistar Institute,
National Institutes of Health,
University of Milan,
Istituto Oncologico Veneto,
National Cancer Institute,
Fondazione IRCCS Istituto Nazionale dei Tumori
show all 7
ORCID:
0000-0002-3026-2314
Observed ORCID:
0000-0002-3026-2314
OpenAlex ID:
A5066838580
Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles
2002
·
Giovanna Andreola
, Licia Rivoltini
, et al.
·
The Journal of Experimental Medicine
·
862
PDF
Human Colorectal Cancer Cells Induce T-Cell Death Through Release of Proapoptotic Microvesicles: Role in Immune Escape
2005
·
Veronica Huber
, Stefano Fais
, et al.
·
Gastroenterology
·
583
PDF
TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site
2016
·
Licia Rivoltini
, Claudia Chiodoni
, et al.
·
Clinical Cancer Research
·
198
PDF
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
1996
·
D J Loftus
, C Castelli
, et al.
·
The Journal of Experimental Medicine
·
190
PDF
Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors
2020
·
Cristina Federici
, Eriomina Shahaj
, et al.
·
Frontiers in Immunology
·
175
PDF
Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells
2003
·
Licia Rivoltini
, Chiara Castelli
, et al.
·
The Journal of Immunology
·
124
PDF
Human Melanoma-Reactive CD4+ and CD8+ CTL Clones Resist Fas Ligand-Induced Apoptosis and Use Fas/Fas Ligand-Independent Mechanisms for Tumor Killing
1998
·
Licia Rivoltini
, Marina Radrizzani
, et al.
·
The Journal of Immunology
·
85
PDF
Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
2012
·
Paola Filipazzi
, Lorenzo Pilla
, et al.
·
Clinical Cancer Research
·
78
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).
1998
·
D J Loftus
, P Squarcina
, et al.
·
PubMed
·
77
Identification of a Mutated Receptor-Like Protein Tyrosine Phosphatase κ as a Novel, Class II HLA-Restricted Melanoma Antigen
2003
·
Luisa Novellino
, Nicolina Renkvist
, et al.
·
The Journal of Immunology
·
54
Adoptive transfer of an anti‐MART‐127–35‐specific CD8+ T cell clone leads to immunoselection of human melanoma antigen‐loss variants in SCID mice
2003
·
Francesco Lozupone
, Licia Rivoltini
, et al.
·
European Journal of Immunology
·
51
Natural Killer andNK-LikeT-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96
2005
·
Lorenzo Pilla
, Paola Squarcina
, et al.
·
Cancer Research
·
47
PDF
Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
2003
·
Matteo G Carrabba
, Chiara Castelli
, et al.
·
PubMed
·
41
Recognition of Melanoma-Derived Antigens by CTL: Possible Mechanisms Involved in Down-Regulating Anti-Tumor T-Cell Reactivity
1998
·
Licia Rivoltini
, Douglas J. Loftus
, et al.
·
Critical Reviews in Immunology
·
31
Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide
2007
·
Manuela Iero
, Paola Squarcina
, et al.
·
Cancer Immunology Immunotherapy
·
22
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients
2021
·
Veronica Huber
, Lorenza Di Guardo
, et al.
·
Journal for ImmunoTherapy of Cancer
·
20
PDF
Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma
1988
·
Giuseppe Fossati
, Andrea Anichini
, et al.
·
International Journal of Cancer
·
18
Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)
2018
·
E. Verzoni
, S. Ferro
, et al.
·
Annals of Oncology
·
16
Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening
2022
·
Orazio Fortunato
, Veronica Huber
, et al.
·
Cancer Epidemiology Biomarkers & Prevention
·
11
Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients
2021
·
Darawan Rinchai
, Elena Verzoni
, et al.
·
Clinical and Translational Medicine
·
11
PDF
Broad immunomodulating effect of first-line pazopanib in metastatic renal cell carcinoma patients
2017
·
E. Verzoni
, L. De Cecco
, et al.
·
Annals of Oncology
·
7
Abstract B022: Metabolic and immunologic effects of the fasting mimicking diet in cancer patients
2018
·
Filippo de Braud
, Claudio Vernieri
, et al.
·
Molecular Cancer Therapeutics
·
3
Vaccination with survivin and PSMA-derived peptides for controlling biochemical recurrence in prostate cancer: A pilot study
2009
·
R. Valdagni
, A. Marrari
, et al.
·
Journal of Clinical Oncology
·
3
A platform for high-resolution immune liquid biopsy analysis to predict response in patients with renal cell carcinoma treated with nivolumab or cabozantinib: Preliminary data from I-RENE trial (Meet-URO 8 study).
2023
·
Elena Verzoni
, Veronica Huber
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Pazopanib induces dramatic but transient contraction of myeloid suppression compartment in favor of adaptive immunity
2020
·
Darawan Rinchai
, Elena Verzoni
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
2
PDF
Show more works
View as search
Works count:
79
Citation count:
2,715
H-index:
17
I10-index:
20
Year
Topic
Type